外源性性激素与跨性别患者术后恶心呕吐风险
该回顾性队列研究基于TriNetX数据库,比较接受性别肯定激素治疗(GAHT)的跨性别患者与顺性别患者术后使用补救止吐药的风险。结果显示,接受雌激素GAHT的跨性别女性在睾丸切除和乳房增大术后补救止吐药使用率显著高于顺性别对照;接受睾酮GAHT的跨性别男性在子宫切除术后补救止吐药使用率显著低于顺性别女性。
要点
- 跨性别女性使用雌激素GAHT与睾丸切除及乳房增大术后补救止吐药风险升高相关。
- 跨性别男性使用睾酮GAHT与子宫切除术后补救止吐药风险降低相关。
- 需针对跨性别患者个体化制定围术期止吐预防策略。
核心结论
- 跨性别女性(AMAB)使用雌激素GAHT在睾丸切除和乳房增大术后补救止吐药使用率高于顺性别男性和女性。
- 跨性别男性(AFAB)使用睾酮GAHT在子宫切除术后补救止吐药使用率低于顺性别女性。
研究设计与样本
- 回顾性队列研究,使用TriNetX数据库,按手术类型分别比较跨性别与顺性别患者。
- 子宫切除术比较跨性别男性(AFAB)与顺性别女性;睾丸切除术比较跨性别女性(AMAB)与顺性别男性;乳房增大术比较跨性别女性(AMAB)与顺性别女性。
- 采用倾向性评分匹配年龄、种族、族裔、尼古丁依赖和烟草使用。
关键数值与推荐
- 主要结局为手术当日或次日给予补救止吐药,包括氟哌利多、异丙嗪、茶苯海明、甲氧氯普胺和丙氯拉嗪。
临床怎么用
- 对使用雌激素GAHT的跨性别女性在睾丸切除和乳房增大术后应加强止吐预防。
- 对使用睾酮GAHT的跨性别男性在子宫切除术后可考虑相应调整止吐策略。
- 倡导基于激素治疗状态的个体化围术期止吐管理以促进公平麻醉照护。
局限性
- 回顾性设计限制因果推断。
- 存在编码错误和残余混杂的可能。
- 需前瞻性研究验证并阐明GAHT时机、剂量和持续时间对PONV风险的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Postoperative nausea and vomiting (PONV) remain a significant consideration in perioperative care; however, the incidence and risk factors of PONV in transgender patients are poorly understood. This study investigated the rates of PONV in transgender patients receiving gender-affirming hormone therapy (GAHT) compared to cisgender patients. We postulate that exogenous testosterone GAHT reduces the risk of PONV while exogenous estrogen GAHT increases the risk of PONV. METHODS: This retrospective cohort study was conducted using the TriNetX database. Patients were divided into 2 groups: transgender and cisgender. Separate analyses were performed for hysterectomies (transgender male [assigned female at birth, AFAB] versus cisgender female), orchiectomies (transgender female [assigned male at birth, AMAB] versus cisgender male), and augmentation mammoplasties (transgender female [AMAB] versus cisgender female). Propensity score matching was performed for age, race, and ethnicity (White, Black, Hispanic, or Latino), which were treated as social and demographic variables as recorded in the database, nicotine dependence, and tobacco use. The primary outcome was the administration of a rescue antiemetic, defined as droperidol, promethazine, dimenhydrinate, metoclopramide, and prochlorperazine, on the day of or day following surgery. RESULTS: Following hysterectomy, there was a significant difference in the risk of rescue antiemetic use between transgender males (AFAB) taking testosterone GAHT (62.11%, 1031 of 1660) and cisgender females (65.90%, 1094 of 1660) ( P = .0227). Following orchiectomy, there was a significant difference in the risk of rescue antiemetic use between transgender females (AMAB) taking estrogen GAHT (51.15%, 445 of 870) and cisgender males (36.78%, 320 of 870) ( P < .0001). Following augmentation mammoplasty, there was a significant difference in the risk of rescue antiemetic use between transgender females (AMAB) taking estrogen GAHT (53.29%, 356 of 668) and cisgender females (43.71%, 292 of 668) ( P = .0005). CONCLUSIONS: Transgender female (AMAB) patients on estrogen GAHT required rescue antiemetics more often than cisgender males and cisgender females after orchiectomies and augmentation mammoplasties. Transgender male (AFAB) patients on testosterone GAHT required rescue antiemetics less often than cisgender females after hysterectomies. These findings underscore the need for individualized perioperative care and antiemetic prophylaxis to promote equitable anesthetic care for transgender patients. This study's retrospective design limits causal inference and is subject to coding errors and residual confounding. Prospective studies with detailed perioperative and hormonal data are needed to validate these findings and clarify how the timing, dosage, and duration of GAHT influence PONV risk.
引用
- Soloniuk LJ, Sran J, Baker C, et al. Exogenous Sex Hormones and Postoperative Nausea and Vomiting Risk in Transgender Patients. Anesth Analg. 2026. PMID: 41628415. doi:10.1213/ANE.0000000000007929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。